Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Item

http://www.wikidata.org/entity/Q38650400

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Netupitant/Palonosetron: A Rev ...... y-Induced Nausea and Vomiting.

@en

type

Item

label

Netupitant/Palonosetron: A Rev ...... y-Induced Nausea and Vomiting.

@en

prefLabel

Netupitant/Palonosetron: A Rev ...... y-Induced Nausea and Vomiting.

@en

P1476

Netupitant/Palonosetron: A Rev ...... y-Induced Nausea and Vomiting.

@en

P2860

Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review

Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data

International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice.

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.

Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Update and new trends in antiemetic therapy: the continuing need for novel therapies.

In vitro and in vivo pharmacological characterization of the novel NK₁ receptor selective antagonist Netupitant.

P2888

s40265-015-0512-9

P304

2131-2141

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-015-0512-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gillian M Keating

P577

2015-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1034213041

http://www.w3.org/2001/XMLSchema#string

P698

26613606

http://www.w3.org/2001/XMLSchema#string